Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Income from Continuing Operations of 1031400000.0 for Q1 2026, up 59.59% year-over-year from 646300000.0 in Q1 2025, and down 13.41% quarter-over-quarter from 1191100000.0 in Q4 2025.
Vertex Pharmaceuticals (VRTX) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 1031400000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 59.59% year-over-year to 1031400000.0; the TTM figure through Mar 2026 stood at 4338300000.0 (up 538.7% YoY), while the FY2025 annual figure was 3953200000.0, up 838.09% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 1031400000.0, down from 1191100000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1191100000.0 in Q4 2025, with the low at 3593600000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 930500000.0 (2022), against an average of 670035294.12.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations soared 1109.7% in 2022, then slumped 492.44% in 2024.
- Vertex Pharmaceuticals' Income from Continuing Operations stood at 818900000.0 in 2022, then climbed by 18.31% to 968800000.0 in 2023, then retreated by 5.76% to 913000000.0 in 2024, then soared by 30.46% to 1191100000.0 in 2025, then retreated by 13.41% to 1031400000.0 in 2026.
- Business Quant data shows VRTX's Income from Continuing Operations at 1031400000.0 in Q1 2026, 1191100000.0 in Q4 2025, and 1082900000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.10 Bn |
| Mar 31, 2026 | 1.03 Bn |
| Dec 31, 2025 | 1.19 Bn |
| Sep 30, 2025 | 1.08 Bn |
| Jun 30, 2025 | 1.03 Bn |
| Mar 31, 2025 | 646.30 Mn |
| Dec 31, 2024 | 913.00 Mn |
| Sep 30, 2024 | 1.05 Bn |
| Jun 30, 2024 | -3.59 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 968.80 Mn |
| Sep 30, 2023 | 1.04 Bn |
| Jun 30, 2023 | 915.70 Mn |
| Mar 31, 2023 | 699.80 Mn |
| Dec 31, 2022 | 818.90 Mn |
| Sep 30, 2022 | 930.50 Mn |
| Jun 30, 2022 | 810.50 Mn |
| Mar 31, 2022 | 762.10 Mn |
| Dec 31, 2021 | 770.10 Mn |
| Sep 30, 2021 | 851.90 Mn |